Blitzer M L, Loh E, Roddy M A, Stamler J S, Creager M A
Vascular Medicine and Atherosclerosis Unit, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
J Am Coll Cardiol. 1996 Sep;28(3):591-6. doi: 10.1016/0735-1097(96)00218-5.
This investigation sought to determine whether endothelium-derived nitric oxide contributes to hypoxia-induced systemic vasodilation and pulmonary vasoconstriction in humans.
Endothelium-derived nitric oxide contributes to basal systemic and pulmonary vascular resistance. During hypoxia, systemic vasodilation and pulmonary vasoconstriction occur. There are some data indicating that endothelium-derived nitric oxide mediates changes in vascular resistance during hypoxia, but much of it is contradictory, and none has been derived from normal humans.
The hemodynamic effects of NG-monomethyl-L-arginine (L-NMMA), a nitric oxide synthase inhibitor, were studied in healthy volunteers under normoxic and hypoxic conditions. A Swan-Ganz catheter and radial artery cannula were inserted to measure right atrial, pulmonary artery, pulmonary capillary wedge and systemic blood pressures. Cardiac output was measured by thermodilution. Systemic vascular resistance and pulmonary vascular resistance were calculated. The pharmacokinetics of L-NMMA (300 mg intravenously) was studied during normoxia in six subjects. Hypoxia was induced in eight subjects who inspired a mixture of nitrogen and oxygen through a gas blender adjusted to reduce the partial pressure of oxygen from (mean +/- SE) 98 +/- 4 to 48 +/- 1 mm Hg.
During normoxia, L-NMMA increased systemic vascular resistance from 1,108 +/- 74 to 1,705 +/- 87 dynes-s-cm-5 and increased pulmonary vascular resistance from 60 +/- 5 to 115 +/- 9 dynes-s-cm-5 (p < or = 0.01 for each). Peak effects occurred within 10 min of L-NMMA administration. Acute hypoxia alone decreased systemic vascular resistance from 1,209 +/- 78 to 992 +/- 58 dynes-s-cm-5 (p < or = 0.05) and increased pulmonary vascular resistance from 92 +/- 11 to 136 +/- 4 dynes-s-cm-5 (p < or = 0.01). While hypoxic conditions were maintained, infusion of L-NMMA increased systemic vascular resistance (to 1,496 +/- 97 dynes-s-cm-5, p < or = 0.01) and increased pulmonary vascular resistance further (to 217 +/- 25 dynes-s-cm-5, p < or = 0.01).
Endothelium-derived nitric oxide contributes to systemic vasodilation and serves as a counterregulatory mechanism to attenuate pulmonary vasoconstriction during acute hypoxia in healthy human subjects.
本研究旨在确定内源性一氧化氮是否参与人类低氧诱导的全身血管舒张和肺血管收缩。
内源性一氧化氮参与基础状态下的全身和肺血管阻力调节。在低氧状态下,会发生全身血管舒张和肺血管收缩。有一些数据表明内源性一氧化氮在低氧时介导血管阻力变化,但其中许多数据相互矛盾,且均非来自正常人类。
在健康志愿者中,研究了一氧化氮合酶抑制剂NG-单甲基-L-精氨酸(L-NMMA)在常氧和低氧条件下的血流动力学效应。插入Swan-Ganz导管和桡动脉插管以测量右心房、肺动脉、肺毛细血管楔压和全身血压。通过热稀释法测量心输出量。计算全身血管阻力和肺血管阻力。在6名受试者常氧状态下研究了L-NMMA(静脉注射300mg)的药代动力学。8名受试者通过气体混合器吸入氮气和氧气的混合气体以诱导低氧,通过调整混合气体使氧分压从(均值±标准误)98±4mmHg降至48±1mmHg。
在常氧状态下,L-NMMA使全身血管阻力从1108±74达因·秒·厘米⁻⁵增加至1705±87达因·秒·厘米⁻⁵,使肺血管阻力从60±5达因·秒·厘米⁻⁵增加至115±9达因·秒·厘米⁻⁵(每项均P≤0.01)。L-NMMA给药后10分钟内出现峰值效应。单纯急性低氧使全身血管阻力从1209±78达因·秒·厘米⁻⁵降至992±58达因·秒·厘米⁻⁵(P≤0.05),使肺血管阻力从92±11达因·秒·厘米⁻⁵增加至136±4达因·秒·厘米⁻⁵(P≤0.01)。在维持低氧状态时,输注L-NMMA使全身血管阻力增加(至1496±97达因·秒·厘米⁻⁵,P≤0.01),并使肺血管阻力进一步增加(至217±25达因·秒·厘米⁻⁵,P≤0.01)。
内源性一氧化氮参与全身血管舒张,并在健康人类受试者急性低氧期间作为一种对抗调节机制减弱肺血管收缩。